Biopharma Investors, Companies Learning To Adjust To Financial Market Realities
When Cycle Will Spin Out Of Downturn Is Anyone’s Guess
Raising money will be difficult for the foreseeable future, so every part of the ecosystem from start-ups to public companies to VC firms is figuring out how to survive until cash is easily accessible again.
You may also be interested in...
The difficult investment environment has made it harder to build newcos, but panelists at the Galien Forum talked about how that might help limit some of the me-too companies that proliferate when financing is easier.
The three-day meeting in Carlsbad, CA, included commentary from numerous executives and investors in the cell and gene therapy space. Here are some of the biggest takeaways.
Private Company Edition: Iambic, formerly known as Entos, closed a $100m series B venture capital round to advance its AI-discovered therapeutics. Also, Evozyne raised $81m and Acesion brought in €45m in series B rounds, while Mogrify added $10m to bring its series A to $46m.